FAKTOR-OPTIONSSCHEIN - ALNYLAM PHARMACEUTICALS INC Share Price

Certificat

DE000SH14FS4

Delayed Deutsche Boerse AG 01:20:06 24/05/2024 pm IST
0.72 EUR -4.00% Intraday chart for FAKTOR-OPTIONSSCHEIN - ALNYLAM PHARMACEUTICALS INC
Current month+8.70%
3 months-28.57%
Date Price Change
24/24/24 0.72 -4.00%
23/24/23 0.75 -2.60%
22/24/22 0.77 +5.48%
21/24/21 0.73 -1.35%
20/24/20 0.74 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 24, 2024 at 01:20 pm IST

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying ALNYLAM PHARMACEUTICALS, INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SH14FS
ISINDE000SH14FS4
Date issued 27/01/2022
Strike 130.7 $
Maturity Unlimited
Parity 1 : 1
Emission price 10.05
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 31.1
Lowest since issue 0.62

Company Profile

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Sector
-
More about the company

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Alnylam Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
149.4 USD
Average target price
220.4 USD
Spread / Average Target
+47.53%
Consensus